evaluation of ra & pa patients
DESCRIPTION
EVALUATION OF RA & PA PATIENTS. YEAR 2005. GENERAL DEMOGRAPHICS GENDER. PATIENTS’ AGE GROUPS. DURATION OF DISEASE AGE. DIFFERENCE OF MS AT POSTTREATMENT. DIFFERENCE OF VAS (PAIN) AT POSTTREATMENT. DIFFERENCE OF OWB AT POSTTREATMENT. DIFFERENCE OF MHAQ AT POSTTREATMENT. - PowerPoint PPT PresentationTRANSCRIPT
EVALUATION OF EVALUATION OF RA & PA RA & PA
PATIENTSPATIENTS
YEAR 2005YEAR 2005
GENERAL DEMOGRAPHICSGENERAL DEMOGRAPHICSGENDERGENDER
♀ ♀ %% ♂♂ %% Total Total
RARA 313313 75,2475,24 103103 24,7624,76 416416
PAPA 120120 58,8258,82 8484 40,1840,18 204204
ASAS 147147 35,3335,33 269269 64,6764,67 416416
TotalTotal 580580 55,9855,98 456456 44,0244,02 10361036
PATIENTS’ AGE GROUPSPATIENTS’ AGE GROUPS
-20-20 %%21-21-4040 %%
41-41-6060 %% 61+61+ %% Mean Mean
RARA 22 0,480,48 4848 11,5311,53 222222 53,3653,36 144144 34,6134,61 54,7154,71
PAPA 00 00 2626 12,7412,74 132132 64,7064,70 4646 22,5422,54 53,1653,16
ASAS 00 00 8080 19,219,2 281281 67,567,5 5555 13,313,3 49,749,7
Total Total 22 0,190,19 154154 14,8614,86 635635 61,2961,29 245245 23,6423,64 52,452,4
DURATION OF DISEASE AGEDURATION OF DISEASE AGE
-10-10 %%11-11-2020 %%
21-21-3030 %% 31+31+ %% MeanMean
RARA 188188 45,1945,19 143143 34,3734,37 5353 12,7412,74 3232 7,697,69 14,1714,17
PAPA 7878 38,2338,23 9191 44,644,6 2222 10,7810,78 1313 6,376,37 14,0814,08
ASAS 122122 29,329,3 156156 37,537,5 101101 24,324,3 3737 8,98,9 16,916,9
Total Total 388388 37,4537,45 390390 37,6437,64 176176 16,9816,98 8282 7,917,91 15,2515,25
DIFFERENCE OF MS DIFFERENCE OF MS AT POSTTREATMENTAT POSTTREATMENT
MS1MS1
--
MS2MS2
Dec Dec %% IncInc %% SameSame %%
RA-PARA-PA 512512 82,5882,58 1313 2,092,09 9595 15,3215,32
MEANMEAN MS1MS1 MS2MS2
RA-PARA-PA 54,4154,41 20,6620,66
DIFFERENCE OF VAS (PAIN)DIFFERENCE OF VAS (PAIN)AT POSTTREATMENTAT POSTTREATMENT
VAS1VAS1
--
VAS2VAS2
(pain)(pain)
Dec Dec %% IncInc %% SameSame %%
RA-PARA-PA 573573 92,4192,41 4040 6,456,45 77 1,121,12
MEANMEAN VAS1VAS1 VAS2VAS2
RA-PARA-PA 47,9347,93 18,118,1
DIFFERENCE OF OWB DIFFERENCE OF OWB AT POSTTREATMENTAT POSTTREATMENT
OWB1OWB1
--
OWB2OWB2
Dec Dec %% IncInc %% SameSame %%
RA-PARA-PA 575575 92,7492,74 3434 5,485,48 1111 1,771,77
MEANMEAN OWB1OWB1 OWB2OWB2
RA-PARA-PA 51,1851,18 19,0519,05
DIFFERENCE OF MHAQ DIFFERENCE OF MHAQ AT POSTTREATMENTAT POSTTREATMENT
MHAQ1MHAQ1
--
MHAQ2MHAQ2Dec Dec %% IncInc %% SameSame %%
RA-PARA-PA 506506 81,6181,61 3131 55 8383 13,3813,38
MEANMEAN MHAQ1MHAQ1 MHAQ2MHAQ2
RA-PARA-PA 16,1116,11 12,3512,35
DIFFERENCE OF PaGADA DIFFERENCE OF PaGADA AT POSTTREATMENTAT POSTTREATMENT
PaGADA1PaGADA1
--
PaGADA2PaGADA2
Dec Dec %% IncInc %% SameSame %%
RA-PARA-PA 563563 90,890,8 4545 7,257,25 1212 1,931,93
MEANMEAN PaGADA1PaGADA1 PaGADA2PaGADA2
RA-PARA-PA 47,5147,51 19,2219,22
DIFFERENCE OF TJ DIFFERENCE OF TJ AT POSTTREATMENTAT POSTTREATMENT
TJ1TJ1
--
TJ2TJ2Dec Dec %% IncInc %% SameSame %%
RA-PARA-PA 556556 89,6789,67 1212 1,931,93 5252 8,388,38
MEANMEAN TJ1TJ1 TJ2TJ2
RA-PARA-PA 8,748,74 2,242,24
DIFFERENCE OF SwJ DIFFERENCE OF SwJ AT POSTTREATMENTAT POSTTREATMENT
SwJ1SwJ1
--
SwJ2SwJ2
Dec Dec %% IncInc %% SameSame %%
RA-PARA-PA 9090 14,5114,51 1515 2,412,41 515515 83,0683,06
MEANMEAN SwJ1SwJ1 SwJ2SwJ2
RA-PARA-PA 0,750,75 0,290,29
DIFFERENCE OF PGADA DIFFERENCE OF PGADA AT POSTTREATMENTAT POSTTREATMENT
PGADA1PGADA1
--
PGADA2PGADA2
Dec Dec %% IncInc %% SameSame %%
RA-PARA-PA 598598 96,4596,45 1010 1,611,61 1212 1,931,93
MEANMEAN PGADA1PGADA1 PGADA2PGADA2
RA-PARA-PA 42,4842,48 14,9314,93
DIFFERENCE OF DAS 28DIFFERENCE OF DAS 28AT POSTTREATMENTAT POSTTREATMENT
DAS-28 1DAS-28 1
--
DAS-28 2DAS-28 2Dec Dec %% IncInc %% SameSame %%
RA-PARA-PA 601601 96,9396,93 99 1,451,45 1010 1,611,61
MEANMEAN DAS-28 1DAS-28 1 DAS-28 2DAS-28 2
RA-PARA-PA 2,182,18 0,830,83
ANALGESIC USAGE ANALGESIC USAGE AT PRETREATMENTAT PRETREATMENT
AA A-A- %% A+A+ %%
RA-PARA-PA 413413 66,6166,61 207207 33,3833,38
DIFFERENCE OF “A” USAGE AT DIFFERENCE OF “A” USAGE AT POSTTREATMENTPOSTTREATMENT
AA SameSame %% Dec Dec %% IncInc %% Sep Sep %%
RA-RA-PAPA
8989 42,9942,99 7171 34,2934,29 88 3,863,86 3939 18,8418,84
NSAID USAGE NSAID USAGE AT PRETREATMENTAT PRETREATMENT
NSAIDNSAID NSAID-NSAID- %% NSAID+NSAID+ %%
RA-PARA-PA 253253 40,8040,80 367367 59,1959,19
DIFFERENCE OF NSAID USAGE DIFFERENCE OF NSAID USAGE AT POSTTREATMENTAT POSTTREATMENT
NSNS
AIDAID
SameSame %% Dec Dec %% IncInc %% Sep Sep %%
RA-RA-PAPA
243243 66,2166,21 6464 17,4317,43 77 1,91,9 5353 14,4414,44
STEROID USAGE STEROID USAGE AT PRETREATMENTAT PRETREATMENT
STRSTR STR-STR- %% STR+STR+ %%
RA-PARA-PA 484484 78,0678,06 136136 21,9321,93
DIFFERENCE OF “STR” USAGE DIFFERENCE OF “STR” USAGE AT POSTTREATMENTAT POSTTREATMENT
STRSTR SameSame %% Dec Dec %% IncInc %% Sep Sep %%
RA-RA-PAPA
110110 80,8880,88 1414 10,2910,29 44 2,942,94 88 5,885,88
USAGE OF OTHER DRUGS USAGE OF OTHER DRUGS AT PRETREATMENTAT PRETREATMENT
OTHOTH OTHER-OTHER- %% OTHER+OTHER+ %%
RA-PARA-PA 228228 36,7736,77 392392 63,2263,22
DIFFERENCE OF OTHER DRUGS DIFFERENCE OF OTHER DRUGS AT POSTTREATMENTAT POSTTREATMENT
OTHOTH SameSame %% Dec Dec %% IncInc %% Sep Sep %%
RA-RA-PAPA 372372 94,8994,89 99 2,292,29 33 0,760,76 88 2,042,04
MOSTLY SEEN MOSTLY SEEN SECONDARY DISEASESSECONDARY DISEASES
SEC.SEC.
DIS.DIS.
NONO
%%
YESYES
%%
HTHT
%%
CADCAD
%%
DMDM
%%COLDCOLD
%%
CACA
%%DEPRDEPR
%%
TROITROI
%%
OTHOTH
%%
RA-RA-PAPA
272272
43,8743,87
348348
56,1256,12
9494
27,0127,01
3939
11,211,2
2424
6,896,89
3333
9,489,48
1010
2,872,87
1616
4,594,59
5656
16,0916,09
180180
51,7251,72
DAILY POLICLINIC CASESDAILY POLICLINIC CASES
PCPC NONO
%%
YESYES
%%
TRATRA
%%
EYEEYE
%%
URSURS
%%
DERDER
%%
DIARDIAR
%%
PAINPAIN
%%
USEUSE
%%
OTHOTH
%%
RA-RA-PAPA
410410
66,1266,12
210210
33,8733,87
77
3,333,33
44
1,91,9
3737
17,6117,61
1212
5,715,71
1313
6,196,19
120120
57,1457,14
1010
4,764,76
2323
10,9510,95
PATIENTS WHO WERE PATIENTS WHO WERE REFERRED TO HOSPITALREFERRED TO HOSPITAL
CONCONSULTSULT
NONO
%%
MRMR
%%
EYEEYE
%%
ENTENT
%%
DERDER
%%
RHERHE
%%
ORTORT
%%
NEUNEU
%%
RA-RA-PAPA
605605
97,5897,58
44
0,640,64
33
0,480,48
33
0,480,48
11
0,160,16
22
0,320,32
11
0,160,16
11
0,160,16
THANK YOUTHANK YOU
FOR YOUR ATTENTIONFOR YOUR ATTENTION